TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01172483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general practice in primary care and education
Description: education of chronic disorders in PC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal community program
Description: The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
Study: NCT01109563

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Marijuana Check-Ins
Description: The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marijuana Check-Ins
Description: The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
Study: NCT05600504

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02239341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Intervention
Description: Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Conditioning Intervention
Description: Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
Study: NCT02935205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Given PO
Study: NCT01182558

Intervention type: OTHER
Group type: OTHER
Intervention: Hypothenar muscle activation--maximum, voluntary, isometric
Description: Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\]).

Intervention type: OTHER
Group type: OTHER
Intervention: Thenar muscle activation--maximum, voluntary, isometric
Description: Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\]).

Intervention type: OTHER
Group type: OTHER
Intervention: EDB muscle activation--maximum, voluntary, isometric
Description: Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\]).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation of muscle
Description: The muscle on the opposite side will be maintained at rest.
Study: NCT00712205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily 1mcg Placebo for 28days followed by crossover treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: once daily 1mcg Placebo for 28days followed by crossover treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
Study: NCT02263235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: administration of stable isotope-labelled leucine-
Description: - administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: administration of stable isotope-labelled leucine-
Description: - administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collection of CSF, blood, urine, saliva
Description: - administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
Study: NCT01988961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: SC injections
Study: NCT02757976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CRT
Description: Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave \> 7 mV, pacing threshold \< 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LV endocardial CRT
Description: Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
Study: NCT02930486

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZipTight suture endobutton
Description: Zimmer Biomet ZipTight suture endobutton

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tricortical 3.5 mm syndesmotic screw
Description: Depuy Synthes 3.5 mm screw
Study: NCT04205019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neuro-Cells
Description: Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
Study: NCT03081234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant endocrine therapy
Description: Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Description: Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
Study: NCT02721693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill exercise test
Description: Patients are subjected to an incremental exercise test to exhaustion on a treadmill
Study: NCT02453776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRECISION dosing Infliximab
Description: Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
Study: NCT02442674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching active drug
Study: NCT04710966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic debridement
Description: For the arthroscopic debridement, only stump refreshing and surrounding soft tissue cleaning were performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic repair
Description: For the arthroscopic repair, we converted partial tears into full-thickness tears and sutured them.
Study: NCT01644110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB018424/CC-4047
Description: Cohort 1: For patients (1-41) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.~Cohort 2: For patients (42-90) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; the starting dose of pomalidomide is 0.5 mg po once daily.
Study: NCT00860366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uric Acid
Description: 1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
Study: NCT04275765

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2:Behavioral Intervention with nudges & Facebook interaction
Description: Participants will receive nudges and be enrolled to Facebook group for self-learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.
Description: Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
Study: NCT02655744

Intervention type: RADIATION
Intervention: Standard treatment protocol with combined chemoradiation
Study: NCT03311100

Intervention type: OTHER
Intervention: immunohistochemistry assay
Description: biomarkers expression

Intervention type: OTHER
Intervention: immunohistochemistry assay
Description: biomarkers expression

Intervention type: OTHER
Intervention: immunohistochemistry assay
Description: biomarkers expression

Intervention type: OTHER
Intervention: immunohistochemistry assay
Description: biomarkers expression

Intervention type: OTHER
Intervention: immunohistochemistry assay
Description: biomarkers expression

Intervention type: OTHER
Intervention: immunohistochemistry assay
Description: biomarkers expression

Intervention type: OTHER
Intervention: immunohistochemistry assay
Description: biomarkers expression
Study: NCT06171607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Given IV
Study: NCT01983917

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Mobile Application
Study: NCT01555008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: Subjects will receive LX4211 once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 Placebo
Description: Subjects will receive LX4211 placebo once daily for 7 days
Study: NCT02375139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01
Description: complex single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01
Description: complex single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E+M
Description: co-administration of 2 drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E+M
Description: co-administration of 2 drugs
Study: NCT01234792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg Experimental nicotine gum
Description: A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg Nicotine Gum/
Description: A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg Nicotine Gum
Description: A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
Study: NCT02685202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint
Description: A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
Study: NCT01574482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).
Description: 1 = Intervention 1 (1 test product/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters
Description: 2 = Intervention 2 (1 control product/day)
Study: NCT01297387

Intervention type: OTHER
Intervention: PTA BPG procedure,
Description: Surgery PTA or BPG Procedure, according usual local clinical practice
Study: NCT00085423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: ‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
Study: NCT01327261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa + benserazide
Description: Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa + benserazide
Description: Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
Study: NCT03106831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pituitrin infusion
Description: To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Description: To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
Study: NCT02267824

Intervention type: OTHER
Group type: OTHER
Intervention: Fixed Orthodontic Appliance Treatment
Description: Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
Study: NCT02735850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19-IL2
Description: L19-IL2 added to SBRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study: NCT02018783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colgate
Description: Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensodyne
Description: Digital application for 60 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nano P
Description: Slow-speed handpiece with a Robson brush for 10 seconds
Study: NCT04608305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100, low dose (prime)
Description: Single administration of IIBR-100 1\*10E5 pfu/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100, low dose (prime)
Description: Single administration of IIBR-100 1\*10E5 pfu/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100, low dose (prime)
Description: Single administration of IIBR-100 1\*10E5 pfu/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 medium dose (prime)
Description: Single administration of IIBR-100 1\*10E6 pfu/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 medium dose (prime)
Description: Single administration of IIBR-100 1\*10E6 pfu/ml
Study: NCT03440554

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Body Non-Contrast MRI
Description: Whole Body Non-Contrast MRI in Prostate Cancer Patients
Study: NCT02592278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: Application of fluoride varnish every 3 and 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: Application of fluoride varnish every 3 and 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Twice a day brush with fluoride toothpaste.
Study: NCT01653444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1119
Description: biweekly, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1119
Description: biweekly, IV infusion
Study: NCT00365339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir+Ritonavir+Tenofovir
Description: Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir+Ritonavir+Tenofovir+Famotidine
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir+Ritonavir+Tenofovir+Famotidine
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir+Ritonavir+Tenofovir+Famotidine
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir+Ritonavir+Tenofovir+Famotidine
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.